Houston sustainable energy company to be acquired by industry giant for $4.1B

big buyout

Houston-based Archaea Energy's RNG facilities capture waste emissions and convert them into low-carbon fuel. Photo via archaeaenergy.com

BP’s proposed $4.1 billion acquisition of Houston-based Archaea Energy promises to dramatically boost the energy giant’s presence in the biogas market.

Publicly traded Archaea is one of the largest producers of renewable natural gas, or RNG, in the U.S. Its RNG facilities capture waste emissions and convert them into low-carbon fuel. Biogas is produced through the conversion of organic matter like animal manure, trash, plant material, food waste, and sewage.

Through the cash-and-debt deal, BP will gain ownership of 50 RNG and landfill gas-to-energy facilities across the U.S. Once the deal is wrapped up, BP anticipates a 50 percent increase in biogas volumes.

Archaea's development pipeline of more than 80 projects holds the potential for a fivefold increase in RNG volumes at BP by 2030. The pipeline includes 40 RNG projects that Archaea plans to develop with Republic Services, a solid waste disposal company based in Phoenix. Republic Services is a rival of Houston-based Waste Management.

BP expects Archaea to double its biogas-driven EBITDA to about $2 billion within the next eight years. Allied Market Research predicts the global market for waste-derived biogas will jump from $52.9 billion in 2020 to $126.2 by 2030.

The Archaea acquisition is set to close later this year. Once the deal is completed, Archaea will operate as subsidiary of BP, whose U.S. headquarters is in Houston. Archaea relocated its headquarters from Pittsburgh to Houston last year.

“Archaea was founded with a mission to build the world’s leading RNG development company to reduce global emissions and make multigenerational sustainability impacts,” Nick Stork, co-founder and CEO of Archaea, says in a news release. “In a very short period of time, we have rapidly become a leading RNG platform in the U.S., and [the BP acquisition] will further enable this business to realize its full potential.”

BP notes that the demand for biogas is rising thanks to the growth of renewable hydrogen, electric-vehicle charging, and other emerging segments of the energy sector.

“Our biogas team is already one of the leading suppliers of renewable natural gas in North America,” Dave Lawler, chairman and president of BP America, says in a news release. “This deal accelerates our ability to deliver cleaner energy, generate significant earnings in a fast-growing sector, and help reduce emissions. This could help BP take a significant stride toward our net-zero ambition.”

BP America employs nearly 4,000 full-time workers in Houston.

More than half of non-Texans think the Lone Star State is great for business. Photo via Getty Images

Here's what non-Texans think about the Lone Star State's business economy

yeehaw

As Houston and the rest of Texas continue to welcome out-of-state businesses, there’s some affirming news from a new poll. More than half of non-Texans believe the Lone Star State is a good place to launch a business.

The survey, conducted earlier this summer by Austin-based Crosswinds Media & Public Relations and Asbury Park, New Jersey-based Rasmussen Reports, a conservative-leaning polling company, found 53 percent of non-Texans had a positive perception of Texas as a place to do business. Only 23 percent of adults outside Texas had a “bad” or “very bad” view of the state’s business environment, while 24 percent said they were unsure.

The survey questioned 845 American adults who don’t live in Texas.

Thomas Graham, president and CEO of Crosswinds, says the survey results demonstrate that “the brand of the Lone Star State remains strong.”

In recent years, a number of out-of-state companies have been lured by that brand as well as the business climate in Houston. Notable examples include Hewlett Packard Enterprise, NRG Energy, and Axiom Space.

Just this year, several companies based outside Texas have revealed headquarters moves to the Houston area. Among them are:

  • Archaea Energy, which was based in Pittsburgh. The company produces renewable natural gas.
  • CDI Engineering Solutions, which was based in Philadelphia. The company provides engineering and architecture services.
  • DarkPulse, which was based in New York City. The company develops fiber-sensor technology.
  • Noodoe EV, which was based in Irvine, California. The company’s cloud-based platform manages charging stations for electric vehicles.

Jennifer Chang, CEO of Noodoe, says her company relocated its headquarters from Southern California to Texas to take advantage of Houston’s central location.

“Houston has the port and airport capacity we need to efficiently meet the unprecedented demand for EV charging stations,” Chang said in a January news release. “Houston has long been the Energy Capital of the World, mostly because of oil and gas extraction. Noodoe will help the city continue its energy legacy, only this time without fossil fuels.”

The poll from Crosswinds and Rasmussen was completed around the same time that CNBC released its ranking of the best states for doing business. Texas landed in fifth place, down one notch from its perch in CNBC’s 2021 study. A day later, CNBC put out a list of the worst states to live, with Texas appearing at No. 2 behind Arizona.

CNBC notes that skilled workers are flooding Texas, even though the quality of life here raises questions. The new arrivals “are finding limited childcare options, a stressed health care system with the highest rate of uninsured, new curbs on voting rights, and few protections against discrimination,” the cable TV network declares.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings